{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:16:30Z","timestamp":1790388990188,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Respiratory infection with methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) is an increasing complication in cystic fibrosis (CF) that results in accelerated lung function decline and mortality. Vancomycin is considered a first\u2010line intravenous treatment agent for MRSA associated acute pulmonary exacerbations (APEs); however, rates of vancomycin intolerance and resistance have been observed. These factors have led to the exploration of additional treatment options for treating MRSA associated APEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective chart review conducted at a CF center including patients 0 to 21 years of age with CF admitted for an APE and treated with either vancomycin or ceftaroline between January 2016 and August 2018. The primary endpoint was to determine ceftaroline efficacy compared to vancomycin in the treatment of MRSA associated APEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 180 patients included in the study with 90 patients in each antibiotic group. Admission to discharge forced expiratory volume in 1\u2009second (FEV<jats:sub>1<\/jats:sub>) improved in the ceftaroline (66.5% vs 81.1%; <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001) and vancomycin (65.5% vs 77.3%; <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001) treatment groups. No difference existed in mean change in FEV<jats:sub>1<\/jats:sub> (14.1% vs 13.5%; <jats:italic>P<\/jats:italic>\u2009=\u2009.25) or readmissions (15% vs 22; <jats:italic>P<\/jats:italic>\u2009=\u2009.27) between ceftaroline and vancomycin groups, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In this retrospective study, no difference existed between ceftaroline and vancomycin with regard to observed improvement in lung function from admission to discharge. Additionally, no difference was observed in mean FEV<jats:sub>1<\/jats:sub> or readmission rate between the two groups. Ceftaroline may represent an effective and safe intravenous antimicrobial option for targeting MRSA in pediatric CF patients with APEs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ppul.25029","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:58:52Z","timestamp":1598317132000},"page":"3337-3342","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Ceftaroline vs vancomycin for the treatment of acute pulmonary exacerbations in pediatric patients with cystic fibrosis"],"prefix":"10.1002","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6637-625X","authenticated-orcid":false,"given":"Joshua","family":"Branstetter","sequence":"first","affiliation":[{"name":"Department of Pharmacy Children's Healthcare of Atlanta Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Searcy","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Children's of Alabama Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Benner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, McWhorter School of Pharmacy Samford University Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Yarbrough","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Children's of Alabama Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Crowder","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Intermountain Healthcare Taylorsville Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Troxler","sequence":"additional","affiliation":[{"name":"Division of Pediatric Pulmonology University of Alabama at Birmingham Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00068-09"},{"key":"e_1_2_6_3_1","unstructured":"Cystic Fibrosis Foundation Patient Registry: Annual Data Report to the Center Directors 2018.https:\/\/www.cff.org\/Research\/Researcher-Resources\/Patient-Registry\/2018-Cystic-Fibrosis-Foundation-Patient-Registry-Highlights.pdf. Accessed March 14 2020."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2015.10.015"},{"issue":"6","key":"e_1_2_6_5_1","first-page":"623","article-title":"Treatment of pulmonary exacerbations in cystic fibrosis","volume":"8","author":"Smith DJ","year":"2011","journal-title":"Clinical Practice."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.791"},{"key":"e_1_2_6_7_1","first-page":"305","article-title":"The impact of MRSA infection in the airways of children with cystic fibrosis: a case\u2010control study","volume":"104","author":"Cox DW","year":"2011","journal-title":"Ir Med J"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pix043"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.06.002"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/533591"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.10.029"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01388-06"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx084"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200802-327OC"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20604"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.08.006"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014567526"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx084"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001171"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23827"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.10.010"},{"key":"e_1_2_6_22_1","unstructured":"Teflaro\u00ae (ceftaroline fosamil) [package insert]. Allergan Inc; Dublin IR:2011."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01568-12"}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.25029","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ppul.25029","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.25029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:31:56Z","timestamp":1693733516000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.25029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/ppul.25029"],"URL":"https:\/\/doi.org\/10.1002\/ppul.25029","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"value":"8755-6863","type":"print"},{"value":"1099-0496","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,24]]},"assertion":[{"value":"2020-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}